ACT_for Alcohol Use Disorder and Depression

This interventional trial (n=20) will assess the feasibility of combining Acceptance and Commitment Therapy (ACT) with ketamine intervention in patients with alcohol use disorder (AUD) and comorbid treatment-resistant depression (TRD).

Conducted by the Centre hospitalier de l’Université de Montréal (CHUM), this study aims to explore whether ACT can enhance and prolong the antidepressant effects of ketamine while also improving outcomes related to alcohol consumption.

Given the bidirectional relationship between AUD and TRD, and the limitations of conventional treatments, ketamine has emerged as a promising intervention. Prior research has demonstrated its rapid but transient antidepressant effects, as well as its potential in reducing alcohol use when combined with psychotherapy. By integrating ACT—a cognitive-behavioural therapy focused on psychological flexibility—this trial seeks to evaluate its impact on sustaining ketamine’s benefits and addressing the complex interplay of these conditions. The study is expected to begin in May 2025, with primary completion anticipated by November 2025.

Topic Alcohol Use Disorder Addiction Depression Treatment-Resistant Depression
Compound Ketamine Placebo
Country Canada
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.